WT1 gene expression:: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?

被引：20

作者：

Bader, P

Niemeyer, C

Weber, G

Coliva, T

Rossi, V

Kreyenberg, H

Gerecke, A

Biondi, A

机构：

[1] Univ Childrens Hosp, Dept Pediat Hematol & Oncol, D-72070 Tubingen, Germany

[2] Univ Childrens Hosp, Freiburg, Germany

[3] Univ Milano Bicocca, Osped S Gerardo, Pediat Clin, Ctr M Tettamanti, Milan, Italy

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2004年 / 73卷 / 01期

关键词：

WT1 gene expression; minimal residual disease; childhood; myelodysplastic syndromes; juvenile myelo-monocytic leukemia;

D O I：

10.1111/j.1600-0609.2004.00260.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The WT1 gene is considered to be highly expressed in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia and chronic myeloid leukemia and is thought to play a key role in maintaining the viability of leukemia cells. However, little is known about the WT1 gene expression levels in pediatric patients with juvenile myelo-monocytic leukemia (JMML) and myelodysplastic syndromes (MDS). We studied WT1 expression in diagnostic bone marrow (BM) and peripheral blood (PB) samples of 90 patients with JMML, low grade MDS, advanced MDS and myelodysplasia-related AML in BM (n = 20) and PB (n = 18) samples of normal healthy volunteer donors.

引用

收藏

页码：25 / 28

页数：4

相关论文

共 15 条

[1] Juvenile myelomonocytic leukemia [J].

Arico, M ;

Biondi, A ;

Pui, CH .

BLOOD, 1997, 90 (02) :479-488

[2] Characterization of lineage-specific chimaerism in patients with acute leukaemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse [J].

Bader, P ;

Stoll, K ;

Huber, S ;

Geiselhart, A ;

Handgretinger, R ;

Niemeyer, C ;

Einsele, H ;

Schlegel, PG ;

Niethammer, D ;

Beck, J ;

Klingebiel, T .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (04) :761-768

[3] High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome [J].

Bergmann, L ;

Miething, C ;

Maurer, U ;

Brieger, J ;

Karakas, T ;

Weidmann, E ;

Hoelzer, D .

BLOOD, 1997, 90 (03) :1217-1225

[4] The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR [J].

Brieger, J ;

Weidmann, E ;

Maurer, U ;

Hoelzer, D ;

Mitrou, PS ;

Bergmann, L .

ANNALS OF ONCOLOGY, 1995, 6 (08) :811-816

[5] Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System score in patients with myelodysplastic syndromes [J].

Cilloni, D ;

Gottardi, E ;

Messa, F ;

Fava, M ;

Scaravaglio, P ;

Bertini, M ;

Girotto, M ;

Marinone, C ;

Ferrero, D ;

Gallamini, A ;

Levis, A ;

Saglio, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1988-1995

[6] A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases [J].

Hasle, H ;

Niemeyer, CM ;

Chessells, JM ;

Baumann, I ;

Bennett, JM ;

Kerndrup, G ;

Head, DR .

LEUKEMIA, 2003, 17 (02) :277-282

[7] Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia [J].

Inoue, K ;

Ogawa, H ;

Sonoda, Y ;

Kimura, T ;

Sakabe, H ;

Oka, Y ;

Miyake, S ;

Tamaki, H ;

Oji, Y ;

Yamagami, T ;

Tatekawa, T ;

Soma, T ;

Kishimoto, T ;

Sugiyama, H .

BLOOD, 1997, 89 (04) :1405-1412

[8] Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels [J].

Inoue, K ;

Ogawa, H ;

Yamagami, T ;

Soma, T ;

Tani, Y ;

Tatekawa, T ;

Oji, Y ;

Tamaki, H ;

Kyo, T ;

Dohy, H ;

Hiraoka, A ;

Masaoka, T ;

Kishimoto, T ;

Sugiyama, H .

BLOOD, 1996, 88 (06) :2267-2278

[9]

MENSSEN HD, 1995, LEUKEMIA, V9, P1060

[10]

Niemeyer CM, 1997, BLOOD, V89, P3534